|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 408.00 USD | +6.04% |
|
-.--% | -6.49% |
| 05-11 | Virbac continues decline despite positive recommendation |  |
| 04-17 | Virbac: 2026 starts on strong footing |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Veterinary Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 34.13B | |||||
| 12.01B | |||||
| 4.56B | |||||
| 1.92B | - | - | |||
| 1.65B |
- Stock Market
- Stocks
- VIRP Stock
- VRBC.F Stock
- Charts Virbac
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
